Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Reform: Teva Wants Payments To Encourage Generic Substitution

Executive Summary

The overarching political priority for generic drug firms at the moment is creation of a pathway for follow-on biologics. But the industry also hopes that general healthcare reform efforts provide an opportunity to consolidate gains the sector has made around small molecule products as well
Advertisement

Related Content

GPhA’s Deficit Reduction Proposals Focus On Medicare Low-Income Subsidy, REMS Policies
Generics Industry Offers Substitution, Not Rebates, As Health Reform Savings Proposal
Teva’s Health Care Reform Campaign Emphasizes Cost Over Expanded Access
Teva’s Health Care Reform Campaign Emphasizes Cost Over Expanded Access
NCPA’s AMP Legislative Strategy Focuses On Delay, Not Fix, For Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS050728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel